Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: The introduction of direct-acting antivirals (DAA) in 2013 revolutionized hepatitis C virus (HCV) treatment, offering a cure rate >90%. However, this therapy is expensive, and estimations of the number of chronic HCV-infected (CHC) patients and their treatment costs pre-2013 are therefore essential for creating policies and expanding drug access. Herein, we aimed to investigate the number of HCV-related liver disease patients, their healthcare utilization, their annual direct medical costs, and the interferon-based antiviral treatment rates and costs from 2009 to 2013 in South Korea. Methods: The National Health Insurance database was reviewed, and patients diagnosed with CHC from 2009 to 2013 were extracted. Data regarding detailed healthcare utilization, prescribed drugs, and direct medical costs were obtained. For annual direct healthcare cost calculations, a prevalence-based approach was used. Results: Overall, 181,768 CHC patients were identified. In 2013, the annual per-patient costs for chronic hepatitis, liver cirrhosis, hepatocellular carcinoma, and the first year post-liver transplant were 895, 1,873, 6,945, and 67,359 United States dollars, respectively. Interferon-based antiviral therapeutics were prescribed to 25,223 patients (13.9%). Conclusions: Healthcare costs have increased remarkably with increasing liver disease severity. Thus, efforts to stop disease progression are needed. Moreover, the low rate of interferon-based therapy indicates an unmet need for DAA.
Abstract
Background/Aims: The introduction of direct-acting antivirals (DAA) in 2013 revolutionized hepatitis C virus (HCV) treatment, offering a cure rate >90%. However, this therapy is expensive, and estimations of the number of chronic HCV-infected (CHC) patients and their treatment costs pre-2013 are therefore essential for creating policies and expanding drug access. Herein, we aimed to investigate the number of HCV-related liver disease patients, their healthcare utilization, their annual direct medical costs, and the interferon-based antiviral treatment rates and costs from 2009 to 2013 in South Korea. Methods: The National Health Insurance database was reviewed, and patients diagnosed with CHC from 2009 to 2013 were extracted. Data regarding detailed healthcare utilization, prescribed drugs, and direct medical costs were obtained. For annual direct healthcare cost calculations, a prevalence-based approach was used. Results: Overall, 181,768 CHC patients were identified. In 2013, the annual per-patient costs for chronic hepatitis, liver cirrhosis, hepatocellular carcinoma, and the first year post-liver transplant were 895, 1,873, 6,945, and 67,359 United States dollars, respectively. Interferon-based antiviral therapeutics were prescribed to 25,223 patients (13.9%). Conclusions: Healthcare costs have increased remarkably with increasing liver disease severity. Thus, efforts to stop disease progression are needed. Moreover, the low rate of interferon-based therapy indicates an unmet need for DAA.
참고문헌 (18)
- Global report on access to hepatitis C treatment: focus on overcoming barriers, "World Health Organization", World Health Organization, ~ (2016)
- Nguyen LH, "Systematic review: Asian patients with chronic hepatitis C infection", Aliment Pharmacol Ther, 37, pp.921~936 (2013)
- Kim L, "A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples", Epidemiol Health, 36, pp.e2014008~ (2014)
- Jo C, "Cost-of-illness studies: concepts, scopes, and methods", Clin Mol Hepatol, 20, pp.327~337 (2014)
- Kim DY, "A nationwide seroepidemiology of hepatitis C virus infection in South Korea", Liver Int, 33, pp.586~594 (2013)
- 손혜석, "Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005–2012", Clinical and Molecular Hepatology, 21(3), pp.249~256 (2015), 대한간학회
- Cox AL, "MEDICINE: global control of hepatitis C virus", Science, 349, pp.790~791 (2015)
- Rein DB, "The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings", Ann Intern Med, 156, pp.263~270 (2012)
- McAdam-Marx C, "All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective", J Manag Care Pharm, 17, pp.531~546 (2011)
- Razavi H, "Chronic hepatitis C virus (HCV) disease burden and cost in the United States", Hepatology, 57, pp.2164~2170 (2013)
- Ministry of Health & Welfare; National Cancer Center, "Cancer facts & figures 2015" (2015), National Cancer Center
- Lee SS, "Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea", J Med Virol, 88, pp.275~281 (2016)
- 선우림, "만성 C형간염환자의 질병에 대한 지식과 치료지시이행 간의 관계", 가정간호학회지, 22(1), pp.69~77 (2015), 한국가정간호학회
- Hsu PC, "Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection", J Gastroenterol Hepatol, 27, pp.149~157 (2012)
- 김태헌, "만성 C형 간염 치료의 최근 발전", 대한내과학회지, 86(5), pp.563~569 (2014), 대한내과학회[DOI]
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- Honegger JR, "Will there be a vaccine to prevent HCV infection", Semin Liver Dis, 34, pp.79~88 (2014)
- 이선미, "Socioeconomic costs of liver disease in Korea", Clinical and Molecular Hepatology, 17(4), pp.274~291 (2011), 대한간학회